Development of Health-related Quality of Life Instrument for Patients With Cystinosis

ConditionCystinosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age8-26
SponsorCystinose Stiftung

About this trial

Cystinosis is a rare congenital, inherited metabolic disorder that results in the storage of cystine in the cells of many organs of the body. In the infantile nephropathic form of the disease, only the kidney is initially affected by a loss of function, which progresses if untreated and ends in terminal renal failure by early school age. With the prolonged survival of patients due to medication and renal replacement therapy, further loss of function may occur during the course of the disease, especially in the eyes, muscles, endocrine organs and central nervous system.

The quality of life of children with cystinosis is an under-researched topic. The results of the studies available so far show that the young patients and their families report a reduced quality of life and sometimes behavioral problems.

To date, there are no disease specific patient reported outcome measures (PROMs) to measure the quality of life of patients with cystinosis. The aim of the study is to develop a PROM for this target group in several languages (German, English, Spanish and French) from different countries (Germany, United States, Spain, France). The PROM will focus on quality of life and will be developed for children, adolescents, and young adults including parent-report of parents with children aged 0 to 26 years.

Eligibility criteria

Qualifiers

Children, adolescents, and young adults aged 8-26 years (and at least one of their parents) and further parents only of children aged 0-7

patients have a confirmed diagnosis of cystinosis

patients have a sufficient knowledge of the German/ English/ French or Spanish language to participate in focus interviews and complete questionnaires

the informed consent of legal guardian and assent from the patient (if older than eight years) was given

Disqualifiers

severe cognitive impairment

other severe illnesses that strongly determine everyday life

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

300 Participants
are grouped into 1 trial group

Sponsors and collaborators

Cystinose Stiftung

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Sponsor institution

Cystinosis Research Network

Collaborator

Leben eben! Cystinose-Selbsthilfe e.V.

Collaborator